Ustekinumab: moving the target from psoriasis to Crohn's disease

作者：Settesoldi Alessia; Coppola Manuela; Rogai Francesca; Annese Vito^*

来源：Expert Review of Gastroenterology and Hepatology, 2014, 8(1): 5-13.

DOI：10.1586/17474124.2014.850414

• Crohn's disease
• IL-23
• IL-12
• inflammatory bowel disease
• psoriasis
• ustekinumab

Crohn's disease (CD) is an inflammatory bowel disease whose precise etiology is still unknown, and therefore a causal therapy is not yet available. Studies showing the overexpression of IL-12 and IL-23, polymorphisms in genes encoding those cytokines and their receptors and genome-wide association studies have linked Crohn's pathogenesis with IL-12/23 pathway. Ustekinumab is a novel therapeutic IgG(1) kappa monoclonal antibody that modulates Th1 and Th17 function, by blocking the p40 subunit of both IL-12 and IL-23 and preventing the interaction with their receptors on T cells, natural killer cells and antigen-presenting cells with established efficacy in psoriasis. This review will mainly focus on the available evidence on the role of ustekinumab in moderate-to-severe CD. The potential role of this biologic in the armamentarium of CD therapy is discussed.

• 出版日期2014-1